|1.||Di Marzo, Vincenzo: 6 articles (10/2013 - 03/2006)|
|2.||Maione, Sabatino: 3 articles (10/2013 - 12/2007)|
|3.||Morera, Enrico: 2 articles (10/2013 - 12/2007)|
|4.||Comelli, Francesca: 2 articles (10/2013 - 06/2010)|
|5.||Piscitelli, Fabiana: 2 articles (10/2013 - 01/2011)|
|6.||De Chiaro, Maria: 2 articles (10/2013 - 01/2011)|
|7.||Ortar, Giorgio: 2 articles (10/2013 - 12/2007)|
|8.||Costa, Barbara: 2 articles (10/2013 - 06/2010)|
|9.||Boccella, Serena: 2 articles (10/2013 - 01/2011)|
|10.||de Novellis, Vito: 2 articles (01/2011 - 12/2007)|
03/01/2007 - "We investigated if AA-5-HT antagonizes the transient receptor potential vanilloid-1 (TRPV1) channel and, as FAAH and TRPV1 are targets for analgesic compounds, if it exerts analgesia in rodent models of hyperalgesia. "
10/01/2013 - "OMDM198 (0.1-5.0 mg/kg, i.p.) also reversed carrageenan-induced oedema and thermal hyperalgesia in mice with efficacy similar to that of AA-5-HT. "
01/01/2011 - "Finally, a single acute intra-PL/IL cortex microinjection of AA-5-HT transiently decreased allodynia more effectively than URB597 or I-RTX, a selective FAAH inhibitor or a TRPV1 blocker, respectively. "
01/01/2008 - "Notably, N-arachidonoylserotonin completely prevented the formation of ACF with four or more crypts, which have been show to be best correlated with final tumor incidence. "
10/01/2004 - "Endocannabinoids, as well as VDM-11 and AA-5-HT, inhibited the growth in vitro of the transformed rat thyroid cells used to induce the tumors in vivo, and their effect was reversed at least in part by the cannabinoid CB1 receptor antagonist SR141716A. "
06/01/2010 - "Acute inflammation was induced by intraplantar injection of lambda-carrageenan into mice and the anti-inflammatory and anti-nociceptive actions of AA-5-HT were assessed at different doses, time points and treatment schedule. "
03/01/2006 - "VDM-11 significantly elevated anandamide levels in the colon of DNBS-treated mice and concomitantly abolished inflammation, whereas AA-5-HT did not affect endocannabinoid levels and was significantly less efficacious at attenuating colitis. "
04/01/2006 - "In contrast, pre-treatment with SR 141716A (Rimonabant), a CB(1) antagonist, or AA-5-HT, a fatty acid amide hydrolase (FAAH) blocker, did not affect AM 404-evoked hypothermia. "
07/30/1998 - "Finally, AA-5-HT did not activate CB1 cannabinoid receptors since it acted as a very weak ligand in in vitro binding assays, and, at 10-15 mg/kg body weight, it was not active in the 'open field', 'hot plate' and rectal hypothermia tests carried out in mice. "
|5.||CB1 Cannabinoid Receptor (CB1 Receptor)
|6.||Cannabinoid Receptors (Cannabinoid Receptor)
|7.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|8.||Dihydrotachysterol (AT 10)
|9.||cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester (URB597)
|10.||fatty-acid amide hydrolase (fatty acid amide hydrolase)